Unit 09, Office Tower
41st Floor, Room 4109 Convention Plaza 1 Harbour Road
852 2802 9886
Full-time employees: 26,272
|Ms. Y. Y. Tse||Exec. Chairwoman of the Board||4.97M||N/A||1992|
|Mr. Eric S. Y. Tse||CEO & Exec. Director||3.27M||N/A||1996|
|Mr. Ping Tse||Founder & Sr. Exec. Vice Chairman||5.93M||N/A||1952|
|Ms. Cheung Ling Cheng||Exec. Vice Chairwoman of the Board||4.18M||N/A||1964|
|Ms. Mingqin Li||Sr. VP & Exec. Director||169.83k||N/A||1959|
|Mr. Zhoushan Tian||Exec. Director||256.73k||N/A||1964|
|Mr. Hsin Tse||Sr. VP & Exec. Director||825.54k||N/A||1970|
|Ms. Chun Ling Li||Chief Financial Officer||N/A||N/A||1972|
|Sean Chen||Chief Strategy Officer||N/A||N/A||N/A|
|Orphanides George||Chief Scientific Advisor of invoX||N/A||N/A||N/A|
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection. It also provides surgery/analgesia medicines comprising Debaian cataplasms and Gaisanchun soft capsules; and cardio-cerebral vascular medicines, including Yilunping and Kaina tablets. In addition, the company is involved in the long term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Sino Biopharmaceutical Limited’s ISS governance QualityScore as of 1 May 2023 is 8. The pillar scores are Audit: 4; Board: 1; Shareholder rights: 7; Compensation: 10.